Improving lung cancer treatment through biomarker development and collaboration.
Official title: ECOG-ACRIN Thoracic Malignancies Integrated Translational Science Center
Funded at Emory University · NIH-11251412 · Data updated 2026-11-12
This study is looking for new ways to make lung cancer treatments work better by finding special markers in the body, and it’s inviting patients to join clinical trials that explore these exciting new options.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Emory University NIH-funded |
| Lab location | 1 site (Atlanta, United States) |
| Project start | January 2, 2025 |
| Project end | February 28, 2025 |
| Funding year | 2025 |
| Award (this year) | $431,674 |
| NIH project number | 3UG1CA233259-06S1 |
| Project ID | NIH-11251412 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research include individuals diagnosed with lung cancer who may benefit from advanced biomarker-driven therapies.
✕Less likely to help
Patients with lung cancer who are not eligible for clinical trials or those with very late-stage disease may not receive benefit from this research.
What this research studies
This research focuses on enhancing the treatment of lung cancer by developing novel biomarkers that can improve the effectiveness of immunotherapy and targeted therapies. The team at Emory University collaborates with various institutions to share specimens and conduct pilot projects that are directly relevant to clinical trials. By utilizing genomic, epigenomic, and proteomic approaches, the research aims to identify new treatment strategies and overcome resistance to existing therapies. Patients may have the opportunity to participate in clinical trials that utilize these innovative approaches.
Why it matters
Potential benefit: If successful, this research could lead to more effective and personalized treatment options for lung cancer patients.
How similar studies have gone: Previous research has shown success in using biomarker-driven approaches to improve lung cancer treatment outcomes, indicating that this approach is promising.
Where this research is happening
-
Emory University
Atlanta, United States Active
Researchers
- Principal investigator: Leal, Ticiana — Emory University
- Study coordinator: Leal, Ticiana
Related research
Other NIH-funded projects on the same topics.
-
Administrative and Engagement Core for Breast Cancer Breakthrough in Kenya
A national effort in Kenya to speed up how we screen for breast cancer and connect women to treatment, using teamwork across institutions.
-
Collaborative research program to advance patient care
A multi-project research effort at Emory University aims to push forward medical knowledge that could help people with illnesses in the future.
-
Project-003: A multi-partner research program at Emory University
A multi-faceted NIH grant at Emory University aims to advance understanding in a focused area over several years to benefit patients with diseases or conditions connected to the research.
-
Project-002: advancing patient care through coordinated research at Emory
A multi-project NIH grant at Emory aims to translate findings into better care for people with a health condition by coordinating research efforts across teams.
-
Project-006: A Multidisciplinary Emory Initiative to Advance Medical Understanding
A multi-project NIH grant at Emory University aims to push forward medical knowledge in areas that could eventually help patients.
-
Project-005: A multi-component research effort at Emory University
A multi-part NIH grant from Emory University aims to advance understanding in a specific health area over several years with potential patient benefits in the future.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.